Wave Life Sciences

We are a biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health.

[Wave Life Sciences @WaveLifeSci]

We’re presenting data from multiple #RNAEditing programs for #LiverDisease at the EASL Congress on Friday, May 29th. Stop by the sessions to learn more about our AATD and PNPLA3 programs.

#EASLCongress #EASL2026 #Liverhealth #EASL

[Wave Life Sciences @WaveLifeSci]

In Pi*ZZ individuals, Z-AAT aggregates in the liver, where it can result in progressive liver disease. Treatment with WVE-006 led to robust reductions of circulating, mutant Z-AAT from baseline across doses. Thank you Pavel Strnad for sharing your perspective on what this means for people living with AATD.

Dr. Strnad will be presenting data from RestorAATion-2, our clinical trial of WVE-006 for AATD, at #EASLCongress this Friday, May 29. We hope to see you there!

[Wave Life Sciences @WaveLifeSci]

#ICYMI: Our President & CEO, @PaulBolno, participated in an analyst-led fireside chat at the @rbccm Global Healthcare Conference. Listen to the replay: https://t.co/gs8VNgJMNT

[Wave Life Sciences @WaveLifeSci]

We are proud to support AlphaDetect as an inaugural industry sponsor, advancing efforts to improve detection of alpha-1 antitrypsin deficiency (AATD). Through expanded access to free genetic testing and provider support, this collaboration aims to reduce barriers and help identify individuals who are often undiagnosed or misdiagnosed. As a significantly underdiagnosed rare disease, earlier detection can connect more people living with AATD to care, resources, and research that may meaningfully impact their lives. Read more here: https://t.co/RJMmFpuZxu

[Wave Life Sciences @WaveLifeSci]

Yesterday we shared new data that reinforce WVE-006’s potential to address both lung and liver manifestations of AATD with a durable, convenient, and safe therapy capable of recapitulating the protective MZ-like phenotype with monthly dosing. Dr. Kyle Hogarth joined our webcast to offer his perspective on AATD treatment gaps. Watch the replay here: https://t.co/VtbTHhjy9K. #ATS2026

[Wave Life Sciences @WaveLifeSci]

This afternoon we shared a positive update on our RestorAATion-2 clinical trial: WVE-006 (GalNAc-RNA Editing) achieves an MZ-like phenotype across both biweekly and monthly dosing. #ATS2026

Read the press release:
https://t.co/qoIkNwVQDd

Join us for an investor webcast at 5:30 p.m. ET:
https://t.co/VtbTHhk5Zi

[Wave Life Sciences @WaveLifeSci]

Today we provided our 1Q 2026 earnings update. Join us for our investor conference call and webcast today at 8:30 a.m. ET to learn more about our pipeline progress and upcoming milestones. $WVE

Read the press release: https://t.co/RYUv0waIJz

Listen to the webcast: https://t.co/WfNuXJSnj5

[Wave Life Sciences @WaveLifeSci]

On Tuesday, April 28, we will present our 1Q earnings update. Register and listen to the webcast here: https://t.co/QFILRO96df $WVE

[Wave Life Sciences @WaveLifeSci]

This morning we shared new interim data from the Phase 1 portion of INLIGHT demonstrating the continued clinical translation of WVE-007, our GalNAc-siRNA. WVE-007 is a potentially transformational approach for obesity that improves body composition by reducing fat, in particular harmful visceral fat, while preserving muscle. $WVE

Watch this morning’s webcast for more: https://t.co/8caWO49MiP

Read the press release: https://t.co/HlLSLhacAi

[Wave Life Sciences @WaveLifeSci]

Today we announced positive interim Phase 1 data from the INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) for obesity demonstrating that a single 240 mg dose further improved body composition, with clinically meaningful reductions in visceral fat and waist circumference, without muscle loss. $WVE

Read the press release: https://t.co/HlLSLhacAi

Join us at 8:30 a.m. ET for an investor webcast: https://t.co/344TBkEhhr

[Wave Life Sciences @WaveLifeSci]

We’re heading to #OPTBoston this week, where our team will be sharing perspectives across multiple sessions spanning discovery through development. We’re looking forward to exchanging real‑world insights and connecting on how to translate cutting‑edge science into transformative medicines.

See our full speaking schedule below and find more details here: https://t.co/ALaEqykW2W

[Wave Life Sciences @WaveLifeSci]

Our President & CEO, @PaulBolno, will be at #SXSW with @DrAngelaFitch and @ObesityAction's @JNadglowskiOAC speaking on a panel about the Renaissance in Obesity Treatment Innovation.

If you’re in Austin, join in for a dynamic discussion challenging misconceptions about obesity and why effective treatments must focus on improving body composition. At Wave, we’re focused on driving fat loss without muscle loss, with the potential for 1-2x yearly dosing. We look forward to a conversation about what WVE-007 could mean for the future of obesity care.

Details: https://t.co/rxFZsG5m9r

[Wave Life Sciences @WaveLifeSci]

We are pleased to announce the acceptance of a late-breaking oral presentation on WVE-006 (GalNAc-RNA editing) for AATD at #ATS2026!

Read more here: https://t.co/uugQ6qKucY $WVE

[Wave Life Sciences @WaveLifeSci]

Today we announced our 4Q and full year 2025 earnings update. Read the press release and find the link to our 8:30 a.m. conference call here: https://t.co/BZFoyVFx9x

This update includes the latest on our INLIGHT clinical trial of WVE-007 (INHBE GalNAc-siRNA) in individuals living with overweight or obesity and our RestorAATion-2 clinical trial of WVE-006 (GalNAc-RNA editing oligonucleotide) for individuals living with AATD, as well as WVE-008 (GalNAc-RNA editing oligonucleotide) for PNPLA3 I148M liver disease. $WVE

[Wave Life Sciences @WaveLifeSci]

This Thursday at 2:40 p.m. ET, our President & CEO, @PaulBolno, is participating in an analyst-led fireside chat at the virtual @Oppenheimer 36th Annual Healthcare Life Sciences Conference. Register and listen here: https://t.co/Ebv1AnxOjt $WVE

[Wave Life Sciences @WaveLifeSci]

On Thursday, February 26, we will review our 4Q and full year 2025 financial results and provide business updates. Register and listen to the webcast here: https://t.co/VjFH6LGPAf $WVE

[Wave Life Sciences @WaveLifeSci]

Our President & CEO @PaulBolno is presenting at #JPM26 today at 2:15 p.m. PT / 5:15 p.m. ET. Don’t miss this look at what’s next for Wave, including our 2026 strategic priorities and how we’re advancing our leading RNA medicines platform. Join the live webcast here: https://t.co/iI7LczJSaZ #JPM2026 $WVE

[Wave Life Sciences @WaveLifeSci]

Today we highlighted our strategic priorities for 2026, including accelerating development of WVE-007, our investigational INHBE GalNAc-siRNA for obesity, and rapidly advancing our RNA editing portfolio. Highlights from today’s update include:

➡️ We expect to initiate a Phase 2a multidose portion of INLIGHT (WVE-007) in individuals living with obesity with higher BMI and comorbidities in the first half of 2026

➡️ We expect to initiate new trials for WVE-007 as an add-on to incretin and as maintenance post-incretin, in 2026

➡️ We are extending our leadership in RNA editing with multiple data updates for WVE-006 on track for 2026 and our anticipated CTA filing for WVE-008 on track for this year as well

Read more here: https://t.co/F33Q2pTSEO #JPM2026 #JPM26

[Wave Life Sciences @WaveLifeSci]

Today we shared exciting interim data from our ongoing INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) for obesity. A single dose resulted in an improvement in body composition with fat loss similar to GLP-1 at three months without muscle loss. See the presentation: https://t.co/8SOT0Z051L

More key highlights ⬇️

➡️ Following a single subcutaneous 240 mg dose, WVE-007 improved body composition at three months compared to baseline, with a 9.4% reduction in visceral fat (p=0.02), a 4.5% reduction in total body fat (3.5 lbs; p=0.07), and a 3.2% increase in lean mass (4.0 lbs; p=0.01), with no statistically significant changes in the placebo group

➡️ Sustained and robust suppression of serum Activin E supports expectations for continued improvements in body composition, further fat loss, and preserved muscle, with once or twice-yearly dosing

➡️ Generally safe and well tolerated with only mild treatment related adverse events and no clinically meaningful changes in clinical laboratory measurements, including lipid profiles or liver function tests

➡️ Planning underway for Phase 2 trials evaluating WVE-007 both as a monotherapy and an add-on therapy to incretins in populations with higher BMI and related co-morbidities, and as maintenance post-incretin treatment

➡️ Further clinical data updates expected in 1Q 2026, including six-month follow-up from the 240 mg single-dose cohort and three-month follow-up from the 400 mg single-dose cohort

[Wave Life Sciences @WaveLifeSci]

Today we announced positive interim clinical data from the INLIGHT trial of WVE-007 (INHBE GalNAc-siRNA) for obesity demonstrating that a single 240 mg dose improved body composition with fat loss similar to GLP-1 at three months, without muscle loss. $WVE

Read the press release: https://t.co/oKFDHeUKf1

Join us at 8:30 a.m. ET for an investor webcast: https://t.co/Wq9rnT0Lzo